 Lisa Forman
Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 27 | 2023 | 707 | 3.470 |
Why?
| | Cholangitis, Sclerosing | 7 | 2023 | 66 | 1.800 |
Why?
| | Hepatitis C | 8 | 2021 | 219 | 1.470 |
Why?
| | Graft Rejection | 5 | 2018 | 513 | 0.690 |
Why?
| | Cannabinoids | 1 | 2021 | 115 | 0.670 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 27 | 0.600 |
Why?
| | Thrombosis | 1 | 2021 | 298 | 0.600 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 373 | 0.570 |
Why?
| | Living Donors | 7 | 2023 | 270 | 0.560 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 86 | 0.560 |
Why?
| | Alanine Transaminase | 1 | 2017 | 142 | 0.550 |
Why?
| | Hepatitis C, Chronic | 4 | 2015 | 151 | 0.540 |
Why?
| | Hodgkin Disease | 1 | 2017 | 121 | 0.510 |
Why?
| | Glucocorticoids | 2 | 2018 | 532 | 0.490 |
Why?
| | Hepacivirus | 4 | 2021 | 229 | 0.480 |
Why?
| | Gastroenterology | 2 | 2009 | 159 | 0.440 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2023 | 18 | 0.380 |
Why?
| | Liver | 3 | 2017 | 1637 | 0.370 |
Why?
| | Recurrence | 7 | 2023 | 935 | 0.360 |
Why?
| | Liver Diseases | 3 | 2019 | 255 | 0.330 |
Why?
| | Antiviral Agents | 4 | 2015 | 645 | 0.330 |
Why?
| | Liver Failure | 3 | 2008 | 75 | 0.290 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 227 | 0.280 |
Why?
| | Fibrosis | 1 | 2008 | 453 | 0.260 |
Why?
| | Humans | 42 | 2023 | 114711 | 0.250 |
Why?
| | Health Care Rationing | 2 | 2004 | 45 | 0.240 |
Why?
| | Tissue Donors | 4 | 2013 | 316 | 0.230 |
Why?
| | Foreign-Body Migration | 1 | 2004 | 37 | 0.230 |
Why?
| | Ribavirin | 2 | 2005 | 89 | 0.230 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 12 | 0.220 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 36 | 0.220 |
Why?
| | Severity of Illness Index | 5 | 2013 | 2540 | 0.220 |
Why?
| | Resource Allocation | 1 | 2004 | 37 | 0.220 |
Why?
| | Heart Atria | 1 | 2004 | 107 | 0.220 |
Why?
| | Patient Selection | 4 | 2013 | 641 | 0.220 |
Why?
| | Interferon-alpha | 2 | 2005 | 186 | 0.220 |
Why?
| | Insurance | 1 | 2023 | 11 | 0.210 |
Why?
| | Berberine | 1 | 2022 | 6 | 0.210 |
Why?
| | Treatment Outcome | 11 | 2022 | 9089 | 0.200 |
Why?
| | Cholangiocarcinoma | 1 | 2022 | 38 | 0.200 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 56 | 0.200 |
Why?
| | Waiting Lists | 3 | 2013 | 211 | 0.190 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2021 | 17 | 0.190 |
Why?
| | Graft Survival | 6 | 2015 | 446 | 0.180 |
Why?
| | Cholestasis | 1 | 2023 | 225 | 0.170 |
Why?
| | Transplant Recipients | 1 | 2021 | 140 | 0.170 |
Why?
| | Primary Health Care | 1 | 2009 | 1514 | 0.170 |
Why?
| | Thiazoles | 1 | 2000 | 110 | 0.160 |
Why?
| | Postoperative Complications | 3 | 2011 | 2128 | 0.160 |
Why?
| | Middle Aged | 19 | 2021 | 26740 | 0.160 |
Why?
| | Thiazolidinediones | 1 | 2000 | 142 | 0.160 |
Why?
| | Withholding Treatment | 1 | 2018 | 68 | 0.150 |
Why?
| | Time Factors | 6 | 2018 | 6114 | 0.150 |
Why?
| | Ursodeoxycholic Acid | 3 | 2023 | 20 | 0.150 |
Why?
| | Biopsy | 3 | 2017 | 1036 | 0.140 |
Why?
| | Adult | 18 | 2023 | 30562 | 0.140 |
Why?
| | Models, Theoretical | 1 | 2001 | 515 | 0.140 |
Why?
| | Male | 22 | 2021 | 55669 | 0.140 |
Why?
| | Female | 21 | 2021 | 59573 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 45 | 0.130 |
Why?
| | Hepatic Artery | 2 | 2004 | 49 | 0.120 |
Why?
| | Alkaline Phosphatase | 3 | 2023 | 143 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 152 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1342 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1629 | 0.110 |
Why?
| | Pruritus | 2 | 2023 | 59 | 0.110 |
Why?
| | Cholangitis | 1 | 2013 | 19 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 23 | 0.100 |
Why?
| | Aged | 10 | 2017 | 19075 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 245 | 0.100 |
Why?
| | Hepatitis C Antibodies | 1 | 2012 | 9 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 56 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2000 | 1012 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2004 | 211 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 272 | 0.100 |
Why?
| | Retrospective Studies | 11 | 2015 | 12558 | 0.100 |
Why?
| | Bile Acids and Salts | 2 | 2023 | 171 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1040 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 236 | 0.090 |
Why?
| | Hepatitis B, Chronic | 1 | 2010 | 18 | 0.090 |
Why?
| | Liver Neoplasms | 2 | 2004 | 506 | 0.090 |
Why?
| | Hepatitis B Vaccines | 1 | 2010 | 46 | 0.080 |
Why?
| | Duodenostomy | 1 | 2009 | 5 | 0.080 |
Why?
| | Gallbladder | 1 | 2009 | 15 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2010 | 143 | 0.080 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2009 | 25 | 0.080 |
Why?
| | Proportional Hazards Models | 4 | 2015 | 1075 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2382 | 0.080 |
Why?
| | Hepatectomy | 1 | 2009 | 119 | 0.080 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2008 | 24 | 0.080 |
Why?
| | Postoperative Care | 1 | 2009 | 222 | 0.070 |
Why?
| | Coronary Disease | 2 | 2001 | 348 | 0.070 |
Why?
| | Medicine | 1 | 2009 | 102 | 0.070 |
Why?
| | Physicians, Family | 1 | 2009 | 201 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 253 | 0.070 |
Why?
| | Survival Analysis | 3 | 2004 | 1211 | 0.060 |
Why?
| | Donor Selection | 1 | 2006 | 66 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.060 |
Why?
| | Quality of Life | 2 | 2023 | 2353 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 321 | 0.060 |
Why?
| | Intestinal Fistula | 1 | 2004 | 11 | 0.060 |
Why?
| | Vascular Fistula | 1 | 2004 | 14 | 0.060 |
Why?
| | Duodenal Diseases | 1 | 2004 | 9 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2004 | 45 | 0.060 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2004 | 45 | 0.060 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 228 | 0.060 |
Why?
| | Risk Factors | 6 | 2015 | 8634 | 0.050 |
Why?
| | Radiography, Interventional | 1 | 2004 | 105 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 58 | 0.050 |
Why?
| | Cholagogues and Choleretics | 1 | 2023 | 8 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 195 | 0.050 |
Why?
| | Acetates | 1 | 2023 | 95 | 0.050 |
Why?
| | Genotype | 3 | 2015 | 1760 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2022 | 48 | 0.050 |
Why?
| | Sirolimus | 1 | 2003 | 181 | 0.050 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2002 | 12 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 75 | 0.050 |
Why?
| | Vaccination | 1 | 2010 | 1204 | 0.050 |
Why?
| | Survival Rate | 2 | 2004 | 1644 | 0.050 |
Why?
| | Echocardiography | 1 | 2004 | 553 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2004 | 1695 | 0.050 |
Why?
| | Reoperation | 1 | 2003 | 514 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 900 | 0.040 |
Why?
| | Stents | 1 | 2004 | 475 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1430 | 0.040 |
Why?
| | Pravastatin | 1 | 2000 | 28 | 0.040 |
Why?
| | Verapamil | 1 | 2000 | 32 | 0.040 |
Why?
| | Chenodeoxycholic Acid | 1 | 2019 | 12 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 4624 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2001 | 196 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1373 | 0.040 |
Why?
| | Drug Interactions | 1 | 2000 | 338 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 4895 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 249 | 0.040 |
Why?
| | Prevalence | 2 | 2017 | 2251 | 0.040 |
Why?
| | RNA, Viral | 2 | 2015 | 565 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 1728 | 0.040 |
Why?
| | Prognosis | 2 | 2004 | 3330 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2000 | 1121 | 0.030 |
Why?
| | North America | 1 | 2017 | 256 | 0.030 |
Why?
| | Ischemia | 1 | 2000 | 362 | 0.030 |
Why?
| | Chronic Disease | 1 | 2001 | 1579 | 0.030 |
Why?
| | Thrombelastography | 1 | 2015 | 180 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 167 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 493 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1482 | 0.030 |
Why?
| | United States | 3 | 2015 | 12184 | 0.030 |
Why?
| | Viral Load | 1 | 2015 | 405 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 8 | 0.030 |
Why?
| | Pennsylvania | 1 | 2013 | 94 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2013 | 4411 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 811 | 0.030 |
Why?
| | Depression | 1 | 2001 | 1135 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 1994 | 482 | 0.030 |
Why?
| | Interferons | 1 | 2013 | 151 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 201 | 0.020 |
Why?
| | Length of Stay | 2 | 2009 | 962 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 337 | 0.020 |
Why?
| | Risk Assessment | 2 | 2013 | 2968 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 2010 | 25 | 0.020 |
Why?
| | Immunization, Passive | 1 | 2010 | 73 | 0.020 |
Why?
| | Cholangiography | 1 | 2009 | 17 | 0.020 |
Why?
| | Risk | 1 | 2012 | 812 | 0.020 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 38 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 136 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 222 | 0.020 |
Why?
| | DNA, Viral | 1 | 2010 | 350 | 0.020 |
Why?
| | Hypertension, Portal | 1 | 2008 | 61 | 0.020 |
Why?
| | Medical Records | 1 | 2008 | 153 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 729 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| | Mental Disorders | 1 | 1994 | 893 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2000 | 2093 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 319 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1715 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3004 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2087 | 0.010 |
Why?
| | Survival | 1 | 2004 | 37 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 31 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 2003 | 55 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1448 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4100 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 161 | 0.010 |
Why?
| | Probability | 1 | 2004 | 289 | 0.010 |
Why?
| | Tacrolimus | 1 | 2003 | 134 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10472 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 377 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1230 | 0.010 |
Why?
| | Observation | 1 | 2001 | 50 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1167 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 646 | 0.010 |
Why?
| | Health Surveys | 1 | 2001 | 443 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1796 | 0.010 |
Why?
| | Prospective Studies | 1 | 2008 | 6220 | 0.010 |
Why?
| | Registries | 1 | 2004 | 1768 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1621 | 0.010 |
Why?
| | Patient Readmission | 1 | 2001 | 610 | 0.010 |
Why?
| | History, 17th Century | 1 | 1994 | 15 | 0.010 |
Why?
| | History, 18th Century | 1 | 1994 | 18 | 0.010 |
Why?
| | History, Ancient | 1 | 1994 | 48 | 0.010 |
Why?
| | History, 19th Century | 1 | 1994 | 54 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2387 | 0.010 |
Why?
| | Europe | 1 | 1994 | 334 | 0.010 |
Why?
| | History, 20th Century | 1 | 1994 | 264 | 0.010 |
Why?
| | Adolescent | 1 | 2006 | 17856 | 0.000 |
Why?
|
|
Forman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|